Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. 2010

Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China.

Curcumin, a natural compound isolated from turmeric, may inhibit cell proliferation in various tumor cells through a mechanism that is not fully understood. The enhancer of zeste homolog 2 (EZH2) gene is overexpressed in human breast cancers with poor prognosis. In this study, we observed a dose- and time-dependent down-regulation of expression of EZH2 by curcumin that correlates with decreased proliferation in the MDA-MB-435 breast cancer cell line. The curcumin treatment resulted in an accumulation of cells in the G(1) phase of the cell cycle. Further investigation revealed that curcumin-induced down-regulation of EZH2 through stimulation of three major members of the mitogen-activated protein kinase (MAPK) pathway: c-Jun NH2-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) and p38 kinase. These data suggest that an underlying mechanism of the MAPK pathway mediates the down-regulation of EZH2, thus contributing to the anti-proliferative effects of curcumin against breast cancer.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003474 Curcumin A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes. 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-,Curcumin Phytosome,Diferuloylmethane,Mervia,Turmeric Yellow,Phytosome, Curcumin,Yellow, Turmeric
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071221 Enhancer of Zeste Homolog 2 Protein A histone-lysine N-methyltransferase and catalytic subunit of Polycomb Repressive Complex 2. It methylates LYSINE 9 (H3K9me) and LYSINE 27 (H3K27me) of HISTONE H3, leading to transcriptional repression of the affected target gene. EZH2 also methylates non-histone proteins such as GATA4 TRANSCRIPTION FACTOR and the nuclear receptor RORA. It regulates CIRCADIAN CLOCKS via histone methylation of circadian protein gene PROMOTER REGIONS, and its repressive activity is also important for the identity and differentiation of EMBRYONIC STEM CELLS. Enhancer of Zeste Homolog 2,Histone-Lysine N-Methyltransferase EZH2,Lysine N-Methyltransferase-6,EZH2, Histone-Lysine N-Methyltransferase,Histone Lysine N Methyltransferase EZH2,Lysine N Methyltransferase 6
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
January 2009, European journal of pharmacology,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
February 2018, Sheng li xue bao : [Acta physiologica Sinica],
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
August 1993, Cancer letters,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
August 2008, Experimental biology and medicine (Maywood, N.J.),
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
May 2009, Journal of clinical biochemistry and nutrition,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
March 2006, Cancer letters,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
January 2003, Cancer biology & therapy,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
May 2003, Breast cancer research and treatment,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
April 2013, Oncology letters,
Wen-Feng Hua, and Yong-Shui Fu, and Yi-Ji Liao, and Wen-Jie Xia, and Yang-Chao Chen, and Yi-Xin Zeng, and Hsiang-Fu Kung, and Dan Xie
February 2009, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!